A surveillance study found a threefold increase in extensively drug-resistant gonorrhea isolates.
New surveillance data from Europe show a significant rise in azithromycin-resistant gonorrhea in 2022, along with the detection of 2 ceftriaxone-resistant samples.
Diagnostics and health technology company Scout say its test can detect gonorrhea infections in 30 minutes, at less than half the cost of other options.
Data from a phase 3 trial show the antibiotic gepotidacin had a 92.6% microbiologic success rate and was non-inferior to the standard gonorrhea treatment.
WHO researchers say the findings are of "grave concern" for Cambodia and from an international perspective.
The prevalence of ceftriaxone-resistant Neisseria gonorrhoeae isolates nearly tripled in China from 2017 through 2022.
The first-in-class, novel antibiotic showed non-inferiority to the current standard-of-care gonorrhea treatment.
Gonorrhea is one of the most common sexually transmitted infections, with more than 82 million people diagnosed annually.
The portable test from Visby Medical will be able to detect gonorrhea and assess susceptibility to ciprofloxacin.
The low-cost lateral flow assay showed high sensitivity and specificity in 400 patients with symptoms of gonorrhea, and results were available in 30 minutes.
